$18.87 Million in Sales Expected for ChromaDex Co. (NASDAQ:CDXC) This Quarter

Equities analysts expect ChromaDex Co. (NASDAQ:CDXCGet Rating) to report sales of $18.87 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for ChromaDex’s earnings. The highest sales estimate is $21.00 million and the lowest is $16.07 million. ChromaDex posted sales of $17.70 million in the same quarter last year, which suggests a positive year over year growth rate of 6.6%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that ChromaDex will report full-year sales of $78.29 million for the current fiscal year, with estimates ranging from $75.80 million to $81.20 million. For the next year, analysts expect that the firm will post sales of $98.82 million, with estimates ranging from $97.95 million to $99.50 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow ChromaDex.

ChromaDex (NASDAQ:CDXCGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ChromaDex had a negative return on equity of 81.32% and a negative net margin of 39.25%. The company had revenue of $17.26 million for the quarter, compared to analyst estimates of $17.42 million. During the same quarter last year, the company earned ($0.12) EPS.

Several research analysts have issued reports on CDXC shares. HC Wainwright reduced their price objective on ChromaDex from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, April 18th. StockNews.com started coverage on ChromaDex in a research note on Thursday, March 31st. They set a “hold” rating on the stock. B. Riley dropped their price objective on ChromaDex from $8.00 to $6.00 in a report on Friday, May 13th. Oppenheimer reduced their target price on shares of ChromaDex to $7.00 and set a “na” rating on the stock in a research note on Tuesday, May 17th. Finally, Zacks Investment Research raised shares of ChromaDex from a “sell” rating to a “hold” rating in a research note on Wednesday, May 18th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.05.

In related news, CEO Robert N. Fried purchased 25,000 shares of the stock in a transaction dated Wednesday, March 16th. The stock was bought at an average cost of $2.16 per share, with a total value of $54,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 11.80% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in CDXC. Tieton Capital Management LLC grew its position in shares of ChromaDex by 242.8% in the 1st quarter. Tieton Capital Management LLC now owns 1,428,742 shares of the company’s stock valued at $3,515,000 after purchasing an additional 1,012,016 shares during the period. Renaissance Technologies LLC increased its position in shares of ChromaDex by 1,004.0% during the first quarter. Renaissance Technologies LLC now owns 420,501 shares of the company’s stock worth $1,034,000 after acquiring an additional 382,413 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of ChromaDex by 9.5% during the first quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company’s stock worth $6,842,000 after acquiring an additional 240,414 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in ChromaDex in the 4th quarter valued at $297,000. Finally, Goldman Sachs Group Inc. lifted its position in ChromaDex by 22.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 431,126 shares of the company’s stock valued at $1,613,000 after acquiring an additional 78,834 shares in the last quarter. 29.64% of the stock is owned by institutional investors.

Shares of CDXC stock opened at $1.90 on Friday. ChromaDex has a 1 year low of $1.51 and a 1 year high of $10.78. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $2.87.

ChromaDex Company Profile (Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Featured Stories

Get a free copy of the Zacks research report on ChromaDex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ChromaDex (NASDAQ:CDXC)

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.